Q1 2024

Filed May 14, 2024 · 10-Q · 44 days after period end · 0000950170-24-059493

Q1 2024 · 10-Q

Revenue

$0.00

no prior Q1 2023 on file

Net Income

-$19.56M

N/M vs Q1 2023

EPS Diluted

-$2.44

N/M vs Q1 2023

Operating Income-$21,453,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2024	Q1 2023	Q1 2022	Q1 2021
Revenue	$0.00	—	$0.00	$4.65M
Net Income	-$19.56M	-$19.61M	-$23.39M	-$20.38M
EPS Diluted	-$2.44	-$72.20	-$0.67	-$0.60

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR